ReviewSAGE open medicine2020
Vasoplegia after cardiopulmonary bypass: A narrative review of pathophysiology and emerging targeted therapies.
Review in SAGE open medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 46 citations in OpenAlex.
- Volatile versus propofol sedation after cardiac valve surgery: a single-center prospective randomized controlled trial.Critical care (London, England) · 2024Trial
- Vasoplegia in Cardiac Surgery and Mechanical Circulatory Support: From Cardiopulmonary Bypass to Advanced Circulatory Support Devices.Journal of cardiovascular development and disease · 2026Review
- Review
- Outcomes and Risk Factors for Postoperative Vasoplegia Following Implant of Left Ventricular Assist Devices.Journal of the American Heart Association · 2026Article
- Left Atrial Dissection After Mitral and Aortic Valve Replacement: The Importance of Early Diagnosis of a Rare Entity.Reports (MDPI) · 2025Article
- Hydroxocobalamin for vasoplegia in cardiac surgery: a retrospective cohort analysis.British journal of anaesthesia · 2025Article
- Impaired contractile response of human peripheral arterioles to angiotensin II after cardiopulmonary bypass.Surgery · 2025Article
- Kinetics of Renin Concentrations in Infants Undergoing Congenital Cardiac Surgery.Journal of intensive care medicine · 2025Article
- Vasoplegic Syndrome Following Bypass: A Comprehensive Review of Pathophysiology and Proposed Treatments.Cureus · 2025Review
- Article
- Vasoplegia Following Complex Spine Surgery: Incidence and Risk.Global spine journal · 2024Article
- Article
- Comment on: "Methylene Blue-Induced Serotonin Toxicity: Case Files of the Medical Toxicology Fellowship at the New York City Poison Control Center".Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2024Article
- Vasoplegic Syndrome and Anaesthesia: A Narrative Review.Turkish journal of anaesthesiology and reanimation · 2023Article
- Hydroxocobalamin as Rescue Therapy in a Patient With Refractory Amlodipine-Induced Vasoplegia.Cureus · 2023Article
- Cerebral effects of different prime solutions used during cardiopulmonary bypass.Turk gogus kalp damar cerrahisi dergisi · 2023Article
- Article
- Protocol Compliance Guiding Angiotensin II Use in Post Cardiovascular Surgery Vasoplegia.Critical care explorations · 2022Article
- Effect of preoperative renin-angiotensin system blockade on vasoplegia after cardiac surgery: A systematic review with meta-analysis.World journal of cardiology · 2022Article
- Vasoplegia: Mechanism and Management Following Cardiopulmonary Bypass.The Eurasian journal of medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease remains the leading cause of death in the United States, and cardiopulmonary bypass is a cornerstone in the surgical management of many related disease states. Pathophysiologic changes associated both with extracorporeal circulation and shock can beget a syndrome of low systemic vascular resistance paired with relatively preserved cardiac output, termed vasoplegia. While increased vasopressor requirements accompany vasoplegia, related pathophysiologic mechanisms may also lead to true catecholamine resistance, which is associated with further heightened mortality. The introduction of a second non-catecholamine vasopressor, angiotensin II, and non-specific nitric oxide scavengers offers potential means by which to manage this challenging phenomenon. This narrative review addresses both the definition, risk factors, and pathophysiology of vasoplegia and potential therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.